Multiple unspecified molecular targets

Multiple unspecified molecular targets is a descriptive category used in pharmacology to identify drugs or compounds whose specific biological targets have not been definitively characterized. This designation is often found in databases like ChEMBL or the Therapeutic Target Database (TTD) when a compound's activity is documented through phenotypic assays rather than target-based screens (Gaulton et al., 2012, Nucleic Acids Research). It encompasses substances that may interact with a wide variety of proteins, lipids, or nucleic acids, as well as those whose primary therapeutic effect is the result of polypharmacology (Moffat et al., 2017, Nature Reviews Drug Discovery). Historically, many drugs, including certain general anesthetics and traditional herbal medicines, were utilized clinically long before their specific molecular interactions were understood. From a drug development perspective, this classification presents significant challenges, as the lack of a defined target complicates the optimization of potency and the prediction of side effects. Consequently, compounds in this category often require extensive target deconvolution studies to satisfy modern regulatory requirements for mechanistic clarity (Santos et al., 2017, Nature Reviews Drug Discovery). For biotech analysts, this label serves as a marker for high mechanistic risk and the potential for unforeseen off-target toxicities.

Other names

Unspecified targetsUnknown targetsNon-specific molecular targetsPolypharmacological targets

The mechanism of action is typically unknown, poorly defined, or involves the simultaneous modulation of multiple distinct biological pathways and molecular entities.